8-K - Sensei Biotherapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Sensei Biotherapeutics, Inc. appointed Christopher W. Gerry and Phillip B. Donenberg as new directors to its board, increasing the board size from three to five members effective February 13, 2026. This change in board composition is a key governance event for investors.

Key Takeaways

1The board of directors increased in size from three members to five members.

2Christopher W. Gerry (age 46) was appointed as a new director effective February 13, 2026.

3Phillip B. Donenberg (age 65) was appointed as a new director effective February 13, 2026.

4Mr. Gerry is the President, Principal Executive Officer and General Counsel of the Company.

5Mr. Donenberg will be compensated as a director in accordance with the Company's non-employee director compensation program.

6Each new director will enter into the Company's standard form of indemnification agreement.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment o

Management Change

Executive & Director Changes

Christopher W. Gerry

Director

Appointment

Effective: 2026-02-13

Board voted to increase size and appoint new directors

Phillip B. Donenberg

Director

Appointment

Effective: 2026-02-13

Board voted to increase size and appoint new directors

Exhibits (1)

8-K